First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

Andrea Molckovsky; Lillian L Siu

doi:10.1186/1756-8722-1-20

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

J Hematol Oncol. 2008 Oct 29:1:20. doi: 10.1186/1756-8722-1-20.

Authors

Andrea Molckovsky¹, Lillian L Siu

Affiliation

¹ Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada. lim.che.kang@sgh.com.sg

Abstract

This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.

Publication types

Congress

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase I as Topic
Humans
Neoplasms / drug therapy*

Substances

Antineoplastic Agents